The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease

Altomare, Alberto; Corrado, Addolorata; Maruotti, Nicola; Cici, Daniela; Cantatore, Francesco Paolo

doi:10.1007/s11033-021-06457-z

Cited by 8 publications

(5 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 9 ] Anakinra, which is used to treat PG, is regarded as a safe treatment in terms of side effects. [ 8 ] In our case, severe arthritis after ZA infusion was relieved after a single-day anakinra treatment, and the PG attack did not recur, with the colchicine treatment continuing in the postoperative period.…”

Section: Discussionmentioning

confidence: 61%

“…[ 7 ] Interleukin-1 plays an essential role in PG, both in the inflammatory response to crystals and the pathogenesis of articular cartilage damage. [ 8 ] In case-based studies evaluating the IL-1 antagonist anakinra, it is an effective treatment in acute attack. [ 9 ] Anakinra, which is used to treat PG, is regarded as a safe treatment in terms of side effects.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A case of pseudogout attack after zoledronic acid treatment in primary hyperparathyroidism

Coskun¹

2023

Turk J Phys Med Rehab

View full text Add to dashboard Cite

Pseudogout (PG) is an inflammatory arthropathy that develops due to the accumulation of calcium pyrophosphate dihydrate crystals in synovial structures. Herein, we present a 59-year-old male patient with PG developed as a result of zoledronic acid (ZA) infusion, which was administered due to primary hyperparathyroidism. The patient with parathyroid adenoma was given ZA since the calcium level did not decrease despite intravenous saline and loop diuretic. One day after ZA administration, the patient had severe pain, fever, and swelling in joints. The radiograph showed chondrocalcinosis. Calcium pyrophosphate deposition were observed in the arthrocentesis fluid under polarized light. The patient’s symptoms regressed after anakinra and colchicine treatment. To the best of our knowledge, this is the first case report of a PG attack after ZA treatment for primary hyperparathyroidism. Additionally, there have been few cases of PG after bisphosphonate treatment for osteoporosis in the literature, signifying that more care should be taken when administering bisphosphonate therapy in patients with risk factors.

show abstract

Section: Discussionmentioning

confidence: 61%

Section: Discussionmentioning

confidence: 99%

A case of pseudogout attack after zoledronic acid treatment in primary hyperparathyroidism

Coskun¹

2023

Turk J Phys Med Rehab

View full text Add to dashboard Cite

show abstract

“…Этот факт важен, в том числе исходя из сложности подбора терапии БДПК пациентам преклонного возраста [8]. Считается, что ИЛ-1ра анакинра может быть наиболее приемлемым вариантом лечения острых артритов для пациентов, которым иная терапия противопоказана либо не дает желаемого эффекта, что в пожилом возрасте бывает довольно часто [27]. Однако характеристика артрита при БДПК в разных возрастных группах не различается [5], что согласуется с данными настоящего исследования (возраст наших пациентов, которым назначалась анакинра, варьировал от 49 до 66 лет).…”

Section: Discussionunclassified

The use of Anakinra in treatment of calcium pyrophosphate crystal deposition disease: Analysis of own experience and a literature review

Елисеев¹,

Cheremushkina²,

Насонов

2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Calcium pyrophosphate crystal deposition disease (CPPD) is a disease caused by the deposition of calcium pyrophosphate crystals, mainly in the articular cartilage, and often manifests as severe acute or chronic arthritis. Therapy given in such cases with non-steroidal anti-inflammatory drugs, colchicine, methotrexate and glucocorticoids is often effective. In these cases, the possibility of prescribing biological drugs, primarily interleukin 1 (IL-1) inhibitors, is being considered. The article analyzes the experience of using Anakinra, an IL-1 receptor antagonist, registered in the Russian Federation in 2021, in 5 patients with persistent arthritis in CPPD. The article also presents an analysis of data from key studies on the use of the drug in patients with CPPD.

show abstract

“…Studies have demonstrated that CPP crystals induce the downregulation of the natural IL-1Ra antagonist, resulting in increased IL-1 activity. This leads to a rise in cytokines such as tumor necrosis factor-alpha (TNF-α), IL-6, and chemokines ( 38 , 39 ).…”

Section: Treatment Of Cppdmentioning

confidence: 99%

Recent advances in the therapeutic management of calcium pyrophosphate deposition disease

Voulgari,

Venetsanopoulou,

Drosos

2024

Front. Med.

View full text Add to dashboard Cite

Calcium pyrophosphate deposition (CPPD) disease is a form of crystal-induced arthropathy that arises from the accumulation of calcium pyrophosphate crystals within joints and soft tissues. This process leads to inflammation and damage to the affected joints. It can present asymptomatically or as acute or chronic inflammatory arthritis. Risk factors and comorbidities, including prior joint injury, osteoarthritis, hereditary or familial predisposition, and metabolic diseases, should be evaluated in CPPD cases. The management of CPPD remains a challenge in the sparsity of randomized controlled trials. The lack of such trials makes it difficult to establish evidence-based treatment protocols for CPPD. This review provides an overview of the current pharmacological management of CPPD, focusing on reducing inflammation, alleviating symptoms, and preventing acute flares. Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine are effective in managing acute CPP arthritis. Colchicine may also be used prophylactically to prevent recurrent flares. In cases where other treatments have failed, anakinra, an interleukin-1 receptor antagonist, can be administered to alleviate acute flares. The management of chronic CPP inflammatory arthritis includes NSAIDs and/or colchicine, followed by hydroxychloroquine, low-dose glucocorticoids, and methotrexate, with limited data on efficacy. Tocilizumab can be used in refractory cases. In small studies, synovial destruction using intra-articular injection of yttrium 90 can decrease pain. To date, no disease-modifying therapies exist that reduce articular calcification in CPPD.

show abstract

The role of Interleukin-1 receptor antagonist as a treatment option in calcium pyrophosphate crystal deposition disease

Cited by 8 publications

References 58 publications

A case of pseudogout attack after zoledronic acid treatment in primary hyperparathyroidism

A case of pseudogout attack after zoledronic acid treatment in primary hyperparathyroidism

The use of Anakinra in treatment of calcium pyrophosphate crystal deposition disease: Analysis of own experience and a literature review

Recent advances in the therapeutic management of calcium pyrophosphate deposition disease

Contact Info

Product

Resources

About